Depression and its relationship with blood levels of acetylcarnitine and coenzyme Q10
- Conditions
- Health Condition 1: F321- Major depressive disorder, singleepisode, moderateHealth Condition 2: F323- Major depressive disorder, singleepisode, severe with psychotic featuresHealth Condition 3: F322- Major depressive disorder, singleepisode, severe without psychotic features
- Registration Number
- CTRI/2019/08/020835
- Lead Sponsor
- Central Institute of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion criteria for patients-
1. Patients diagnosed with moderate or severe depressive episode with or without psychotic symptoms according to ICD 10 diagnostic criteria for research (DCR) (WHO, 1993).
2. Patients of either sex between 18-60 years of age.
3. Patients who are drug naive or drug free for minimum 4 weeks from oral antidepressants.
4. Patients giving written informed consent.
Inclusion criteria for controls-
1. General health questionnaire (GHQ 12) less than or equal to 3.
2. Controls matching age and sex with the patients.
3. Persons giving written informed consent.
Exclusion criteria for patients-
1. Significant co-morbid conditions like chronic kidney disease, cardiovascular disease, cancer, Type I or II diabetes mellitus.
2. Presence of comorbid neurological or other psychiatric disorders.
3. Patients with comorbid substance dependence except caffeine.
4. Patients not giving written informed consent.
Exclusion criteria for controls-
1. General health questionnaire (GHQ 12) score more than 3.
2. Significant co-morbid conditions like chronic kidney disease, cardiovascular disease, cancer, Type I or II diabetes mellitus.
3. Presence of comorbid neurological or other psychiatric disorders.
4. Persons with comorbid substance dependence except caffeine.
5. Persons not giving written informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess levels of acetylcarnitine and coenzyme Q-10 in patients with depressive episode and healthy controls. <br/ ><br>Timepoint: Once cross-sectionally in both cases and controls <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method To see the correlation between levels of acetylcarnitine and coenzyme Q-10 and symptom severity, severity of somatic symptoms and suicidality in depression. <br/ ><br>Timepoint: Once cross-sectionally in cases <br/ ><br>